105 related articles for article (PubMed ID: 27504996)
21. Somatic mutations in the STK11/LKB1 gene are uncommon in rare gynecological tumor types associated with Peutz-Jegher's syndrome.
Connolly DC; Katabuchi H; Cliby WA; Cho KR
Am J Pathol; 2000 Jan; 156(1):339-45. PubMed ID: 10623683
[TBL] [Abstract][Full Text] [Related]
22. [Rare ovarian tumours: therapeutic strategies in 2010, national website observatory for rare ovarian cancers and delineation of referent centers in France].
Ray-Coquard I; Pautier P; Pujade-Lauraine E; Méeus P; Morice P; Treilleux I; Duvillard P; Alexandre J; Lhommé C; Selle F; Guastalla J
Bull Cancer; 2010 Jan; 97(1):123-35. PubMed ID: 20007069
[TBL] [Abstract][Full Text] [Related]
23. Sex cord-stromal tumors of the ovary and testis: their similarities and differences with consideration of selected problems.
Young RH
Mod Pathol; 2005 Feb; 18 Suppl 2():S81-98. PubMed ID: 15502809
[TBL] [Abstract][Full Text] [Related]
24. Research and clinical applications of cancer genome sequencing.
Ku CS; Cooper DN; Ziogas DE; Halkia E; Tzaphlidou M; Roukos DH
Curr Opin Obstet Gynecol; 2013 Feb; 25(1):3-10. PubMed ID: 23108289
[TBL] [Abstract][Full Text] [Related]
25. Genetic changes in nonepithelial ovarian cancer.
Van Nieuwenhuysen E; Lambrechts S; Lambrechts D; Leunen K; Amant F; Vergote I
Expert Rev Anticancer Ther; 2013 Jul; 13(7):871-82. PubMed ID: 23875665
[TBL] [Abstract][Full Text] [Related]
26. BRCA somatic and germline mutation detection in paraffin embedded ovarian cancers by next-generation sequencing.
Mafficini A; Simbolo M; Parisi A; Rusev B; Luchini C; Cataldo I; Piazzola E; Sperandio N; Turri G; Franchi M; Tortora G; Bovo C; Lawlor RT; Scarpa A
Oncotarget; 2016 Jan; 7(2):1076-83. PubMed ID: 26745875
[TBL] [Abstract][Full Text] [Related]
27. The oncogenic roles of DICER1 RNase IIIb domain mutations in ovarian Sertoli-Leydig cell tumors.
Wang Y; Chen J; Yang W; Mo F; Senz J; Yap D; Anglesio MS; Gilks B; Morin GB; Huntsman DG
Neoplasia; 2015 Aug; 17(8):650-60. PubMed ID: 26408257
[TBL] [Abstract][Full Text] [Related]
28. Genetics of gynaecological disorders.
Josifova DJ
Best Pract Res Clin Obstet Gynaecol; 2017 Jul; 42():100-113. PubMed ID: 28684328
[TBL] [Abstract][Full Text] [Related]
29. An In-Depth Look at Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT): Clinical Implications from Recent Molecular Findings.
Lu B; Shi H
J Cancer; 2019; 10(1):223-237. PubMed ID: 30662543
[TBL] [Abstract][Full Text] [Related]
30. Targeted therapies for rare gynaecological cancers.
Manchana T; Ittiwut C; Mutirangura A; Kavanagh JJ
Lancet Oncol; 2010 Jul; 11(7):685-93. PubMed ID: 20362508
[TBL] [Abstract][Full Text] [Related]
31. Mutational analysis (c.402C>G) of the FOXL2 gene and immunohistochemical expression of the FOXL2 protein in testicular adult type granulosa cell tumors and incompletely differentiated sex cord stromal tumors.
Hes O; Vaněček T; Petersson F; Grossmann P; Hora M; Perez Montiel DM; Steiner P; Dvořák M; Michal M
Appl Immunohistochem Mol Morphol; 2011 Jul; 19(4):347-51. PubMed ID: 21293260
[TBL] [Abstract][Full Text] [Related]
32. Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel.
Tung N; Battelli C; Allen B; Kaldate R; Bhatnagar S; Bowles K; Timms K; Garber JE; Herold C; Ellisen L; Krejdovsky J; DeLeonardis K; Sedgwick K; Soltis K; Roa B; Wenstrup RJ; Hartman AR
Cancer; 2015 Jan; 121(1):25-33. PubMed ID: 25186627
[TBL] [Abstract][Full Text] [Related]
33. A current perspective on the pathological assessment of FOXL2 in adult-type granulosa cell tumours of the ovary.
Kommoss S; Gilks CB; Penzel R; Herpel E; Mackenzie R; Huntsman D; Schirmacher P; Anglesio M; Schmidt D; Kommoss F
Histopathology; 2014 Feb; 64(3):380-8. PubMed ID: 24192202
[TBL] [Abstract][Full Text] [Related]
34. FOXL2 is a sensitive and specific marker for sex cord-stromal tumors of the ovary.
Al-Agha OM; Huwait HF; Chow C; Yang W; Senz J; Kalloger SE; Huntsman DG; Young RH; Gilks CB
Am J Surg Pathol; 2011 Apr; 35(4):484-94. PubMed ID: 21378549
[TBL] [Abstract][Full Text] [Related]
35. Profiling of potential driver mutations in sarcomas by targeted next generation sequencing.
Andersson C; Fagman H; Hansson M; Enlund F
Cancer Genet; 2016 Apr; 209(4):154-60. PubMed ID: 26987750
[TBL] [Abstract][Full Text] [Related]
36. Germ cell tumors of the gonads: a selective review emphasizing problems in differential diagnosis, newly appreciated, and controversial issues.
Ulbright TM
Mod Pathol; 2005 Feb; 18 Suppl 2():S61-79. PubMed ID: 15761467
[TBL] [Abstract][Full Text] [Related]
37. Next-generation sequencing - feasibility and practicality in haematology.
Kohlmann A; Grossmann V; Nadarajah N; Haferlach T
Br J Haematol; 2013 Mar; 160(6):736-53. PubMed ID: 23294427
[TBL] [Abstract][Full Text] [Related]
38. Loss of SMARCA4 Expression Is Both Sensitive and Specific for the Diagnosis of Small Cell Carcinoma of Ovary, Hypercalcemic Type.
Conlon N; Silva A; Guerra E; Jelinic P; Schlappe BA; Olvera N; Mueller JJ; Tornos C; Jungbluth AA; Young RH; Oliva E; Levine D; Soslow RA
Am J Surg Pathol; 2016 Mar; 40(3):395-403. PubMed ID: 26645725
[TBL] [Abstract][Full Text] [Related]
39. Genomic insights in gynecologic cancer.
Roddy E; Chapman J
Curr Probl Cancer; 2017; 41(1):8-36. PubMed ID: 28088330
[TBL] [Abstract][Full Text] [Related]
40. SMARCA4 (BRG1) loss of expression is a useful marker for the diagnosis of ovarian small cell carcinoma of the hypercalcemic type (ovarian rhabdoid tumor): a comprehensive analysis of 116 rare gynecologic tumors, 9 soft tissue tumors, and 9 melanomas.
Karanian-Philippe M; Velasco V; Longy M; Floquet A; Arnould L; Coindre JM; Le Naoures-Méar C; Averous G; Guyon F; MacGrogan G; Croce S
Am J Surg Pathol; 2015 Sep; 39(9):1197-205. PubMed ID: 26135561
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
